Innovent Biologics, Inc. (Innovent; ) is a publicly listed Chinese biopharmaceutical company that is headquartered in Suzhou, Jiangsu.
History
Innovent was founded in 2011 by Yu Dechao to focus on the development of a class of biotech drugs known as monoclonal antibodies. It received venture capital funding from Eli Lilly and Company and Fidelity Investments.[2] Other investors included China Life, Hillhouse Capital and Temasek.[3]
In March 2015, Innovent and Eli Lilly agreed to a deal that would pay $56 million upfront to Innovent to co-develop at least three experimental cancer drugs.